Wuhan Jianmin Pharmaceutical Group
Wuhan Jianmin Pharmaceutical engages in the research and development, production, and sale of pharmaceuticals primarily in China.
Launch date
Employees
Market cap
$857m
Enterprise valuation
$771m (Public information from Sep 2024)
Share price
CNY41.65 600976.SS
Wuhan Hubei (HQ)
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|
| Revenues | 2.2b | 2.5b | 3.3b | 3.6b | 4.2b | 40.4b |
| % growth | - | 10 % | 33 % | 11 % | 16 % | - |
| EBITDA | 128m | 182m | 399m | 519m | 626m | - |
| % EBITDA margin | 6 % | 7 % | 12 % | 14 % | 15 % | - |
| Profit | 91.5m | 148m | 325m | 408m | 521m | - |
| % profit margin | 4 % | 6 % | 10 % | 11 % | 12 % | - |
| R&D budget | 41.0m | 37.4m | 52.6m | 73.2m | 74.0m | - |
| R&D % of revenue | 2 % | 2 % | 2 % | 2 % | 2 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Related Content
Recent News about Wuhan Jianmin Pharmaceutical Group
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
